Market Overview

Small Pharmaceuticals Rallying Following FDA Report

Related PGNX
Watch These 5 Huge Put Purchases In Wednesday Trade
7 Biggest Price Target Changes For Monday

The FDA on Monday issued a briefing document ahead of its Anesthetic and Analgesic Drug Products Advisory Committee Meeting scheduled for June 11-12.

The report that new drugs designed to treat opioid-induced constipation may not require large studies to rule out heart risks before approval. According to the report, the length of the studies may be "impractical" given the purpose of the drugs.

The following stocks stand to be affected by the decision and have been reacting to the report.

  • Progenics Pharmaceuticals (NASDAQ: PGNX) up ~9 percent to ~$3.80
  • Nektar Therapeutics (NASDAQ: NKTR) up ~8 percent to ~$12.10
  • Sucampo Pharmaceuticals (NASDAQ: SCMP) up ~3 percent to ~$7.45
  • Synergy Pharmaceuticals (NASDAQ: SGYP) up ~5 percent to $4.45

Posted-In: News FDA


Related Articles (NKTR + PGNX)

View Comments and Join the Discussion!